InnoGI Technologies and Simulations Plus Combine Forces to Offer Next-Level Modeling Solutions for the Prediction of Oral Drug Performance
InnoGI Technologies and Simulations Plus Combine Forces to Offer Next-Level Modeling Solutions for the Prediction of Oral Drug Performance
DELFT, Netherlands, April 17, 2024 /PRNewswire/ -- InnoGI Technologies (formerly The TIM Company) is pleased to announce an exciting, market-driven collaboration with Simulations Plus to combine its TIM Technology, part of the InnoGI SurroGUT platform, with the GastroPlus and ADMET Predictormodelling software offered by Simulations Plus.
荷蘭代爾夫特，2024年4月17日 /PRNewswire/ — InnoGI Technologies（前身爲TIM公司）很高興地宣佈與Simulations Plus進行激動人心的、以市場爲導向的合作，合併其作爲InnoGI SurroGut一部分的TIM技術 平台，使用 GastroPlus 和 ADMET 預測器Simulations Plus 提供的建模軟件。
Understanding drug behavior following oral administration is important because solubility and absorption profiles affect dosing and efficacy. However, dynamic interactions between sparingly-soluble active pharmaceutical ingredients, excipients and the gastrointestinal (GI) environment are oversimplified in all static in vitro dissolution models and are very difficult to model using purely computational (in silico) approaches.
了解口服給藥後的藥物行爲很重要，因爲溶解度和吸收特徵會影響劑量和療效。但是，微溶性活性藥物成分、賦形劑和胃腸道（GI）環境之間的動態相互作用在所有靜態下都過於簡單了 體外 溶出模型，很難使用純粹的計算進行建模（在計算機模擬中) 方法。
To address these challenges and reshape industry norms, we leverage our unique combination of advanced in vitro dynamic dissolution testing with the TIM Technology, accurately mimicking the physiological conditions of the human GI tract, and the GastroPlus and ADMET Predictorsoftware to deliver cutting-edge predictive models.
爲了應對這些挑戰並重塑行業規範，我們利用我們獨特的先進產品組合 體外 使用 TIM 技術進行動態溶出度測試，精確模仿人體胃腸道的生理狀況，以及 GastroPlus 和 ADMET 預測器提供尖端預測模型的軟件。
Behzad Mahdavi, PhD, MBA, CEO of InnoGI Technologies, explains: "By leveraging the unique benefits of our SurroGUTplatform combined with GastroPlus, we will generate cutting-edge predictive models and mechanistic in vitro–in vivo correlations (IVIVCs) that far outperform current approaches. This will improve the predictive accuracy of physiologically-based pharmacokinetic (PBPK) models, physiologically-based biopharmaceutics models (PBBMs), and facilitate the development of mechanistic IVIVCs."
Behzad Mahdavi，博士，工商管理碩士InnoGI Technologies首席執行官解釋說：“通過利用我們的SurroGut的獨特優勢平台與 GastroPlus 相結合，我們將生成尖端的預測模型和機制 體外——體內 相關性（IVIVC）遠遠超過當前的方法。這將提高基於生理的藥代動力學（PBPK）模型、基於生理的生物製藥模型（PBBM）的預測準確性，並促進機械化IVIVC的開發。”
InnoGI Technologies is offering GastroPlus PBPK modelling of oral drug performance in vivo as a standalone service, with the option to integrate in vitro release or dissolution data for a more holistic formulation-oriented approach using advanced TIM Technology or standard US Pharmacopeia (USP) apparatus, and for the development of strong IVIVCs.
InnoGI 科技推出了 GastroPlus 口服藥物性能的 PBPK 建模 在活體中 作爲一項獨立服務，可以選擇集成 體外 發佈或溶出數據，以採用先進的TIM技術或標準的美國藥典（USP）設備以更全面的配方爲導向的方法，並用於開發強效的IVIVC。
About SurroGUTand InnoGI Technologies
InnoGI Technologies, formerly The TIM Company, headquartered in Delft, Netherlands, is an innovative CRO and technology provider for the pharmaceutical and food industries. Its SurroGUTplatform uses advanced in vitro models such as TIM, mimicking the dynamics of the human gut. TIM replicates dynamic pH profiles, peristalsis enzyme secretions and digestive fluid volumes at true-to-life rates. The TIM Technology has been used to evaluate more than 250 active pharmaceutical ingredients in commercial drug products and has guided clients worldwide with decision-making at different stages of oral drug development. This reduces the number of formulation iterations, de-risks clinical trials, and shortens the time to market, as evidenced in more than 260 scientific publications. For more information, visit our website ( or ) or follow us on LinkedIn.
關於 SurroGut和 InnoGI 科技
InnoGi Technologies，前身爲TIM公司，總部位於荷蘭代爾夫特，是製藥和食品行業的創新CRO和技術提供商。是 SurroGut平台使用高級 體外 像 TIM 這樣的模型，模仿人體腸道的動態。TIM 以逼真的速度複製動態 pH 值、蠕動酶分泌物和消化液體積。TIM技術已被用於評估商業藥物產品中的250多種活性藥物成分，並指導全球客戶在口服藥物開發的不同階段做出決策。正如260多份科學出版物所證明的那樣，這減少了配方迭代次數，降低了臨床試驗的風險，並縮短了上市時間。欲了解更多信息，請訪問我們的網站 ( 要麼 ) 或者關注我們 領英。
About GastroPlus
GastroPlus is a sophisticated PBPM/PBBK modeling software platform that is renowned in the pharmaceutical, biotechnology, generics, chemicals, cosmetics and consumer goods industries for its precision and reliability. It is used by more than 200 companies, 350 universities, and 15 regulatory agencies worldwide, and has achieved significant academic and industrial recognition, being cited in more than 1500 peer-reviewed publications. This high level of adoption and citation is a testament to its utility in drug development and regulatory submission processes, providing robust, predictive models of drug and chemical behavior in virtual animals and humans.
關於 GastroPl
GastroPlus 是一個複雜的 PBPM/PBBK 建模軟件平台，因其精度和可靠性而在製藥、生物技術、仿製藥、化工、化妝品和消費品行業中享有盛譽。它被全球200多家公司、350所大學和15個監管機構使用，並獲得了重要的學術和行業認可，在1500多份同行評審出版物中被引用。如此高的採用率和引用率證明了其在藥物研發和監管提交流程中的實用性，爲虛擬動物和人類的藥物和化學行爲提供了可靠的預測模型。
Contact:
Behzad Mahdavi
+13016934141
[email protected]
聯繫人：
Behzad Mahdavi
+13016934141
[電子郵件保護]
SOURCE InnoGI Technologies
來源 InnoGI 科技
譯文內容由第三人軟體翻譯。